-
公开(公告)号：WO2006112925A3
公开(公告)日：2009-04-16
申请号：PCT/US2006005414
申请日：2006-02-16
Applicant: UNIV MARYLAND , LU RUILIANG , FASANO ALESSIO , BROWNLEY JULIE , VOGEL STEFANIE N , LAMMERS KAREN
Inventor： LU RUILIANG , FASANO ALESSIO , BROWNLEY JULIE , VOGEL STEFANIE N , LAMMERS KAREN
IPC: G01N33/53 , A61K39/00 , C07K7/00 , C07K14/715 , G01N33/566
CPC classification number: C07K14/415 , G01N33/566 , G01N2500/00
Abstract: Gliadin is identified as a physiological receptor for CXCR3. Assays for determining modulators of CXCR3 signaling are provided. Fragments of gliadin which function as inhibitors of CXCR3 signaling can be determined. Methods for treating diseases relating to gluten and/or autoimmunity by targeting CXCR3 are provided. Such diseases include celiac disease, gluten sensitivity, gluten allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, inflammatory bowel diseases, systemic lupus erythematosus, psoriasis, scleroderma, and autoimmune thyroid diseases.
Abstract translation: 麦醇溶蛋白被鉴定为CXCR3的生理受体。 提供了确定CXCR3信号传导调节剂的测定方法。 可以测定作为CXCR3信号传导抑制剂起作用的麦醇溶蛋白片段。 提供了通过靶向CXCR3治疗与麸质和/或自身免疫有关的疾病的方法。 这些疾病包括乳糜泻，麸质敏感性，麸质过敏，类风湿性关节炎，多发性硬化，免疫介导或1型糖尿病，炎性肠病，系统性红斑狼疮，牛皮癣，硬皮病和自身免疫性甲状腺疾病。
-
公开(公告)号：WO2006112925A2
公开(公告)日：2006-10-26
申请号：PCT/US2006/005414
申请日：2006-02-16
Applicant: UNIVERSITY OF MARYLAND - BALTIMORE , LU, Ruiliang , FASANO, Alessio , BROWNLEY, Julie , VOGEL, Stefanie, N. , LAMMERS, Karen
Inventor： LU, Ruiliang , FASANO, Alessio , BROWNLEY, Julie , VOGEL, Stefanie, N. , LAMMERS, Karen
IPC: C07K14/705
CPC classification number: C07K14/415 , G01N33/566 , G01N2500/00
Abstract: Gliadin is identified as a physiological receptor for CXCR3. Assays for determining modulators of CXCR3 signaling are provided. Fragments of gliadin which function as inhibitors of CXCR3 signaling can be determined. Methods for treating diseases relating to gluten and/or autoimmunity by targeting CXCR3 are provided. Such diseases include celiac disease, gluten sensitivity, gluten allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, inflammatory bowel diseases, systemic lupus erythematosus, psoriasis, scleroderma, and autoimmune thyroid diseases.
Abstract translation: 麦醇溶蛋白被鉴定为CXCR3的生理受体。 提供了确定CXCR3信号传导调节剂的测定方法。 可以测定作为CXCR3信号传导抑制剂起作用的麦醇溶蛋白片段。 提供了通过靶向CXCR3治疗与麸质和/或自身免疫有关的疾病的方法。 这些疾病包括乳糜泻，麸质敏感性，麸质过敏，类风湿性关节炎，多发性硬化，免疫介导或1型糖尿病，炎性肠病，系统性红斑狼疮，牛皮癣，硬皮病和自身免疫性甲状腺疾病。
-
公开(公告)号：WO2006076587A3
公开(公告)日：2006-07-20
申请号：PCT/US2006/001254
申请日：2006-01-13
Applicant: UNIVERSITY OF MARYLAND BALTIMORE , INSTITUTO SUPERIORE DE SANITA , DE MAGISTRIS, Maria , FASANO, Alessio
Inventor： DE MAGISTRIS, Maria , FASANO, Alessio
IPC: A61K39/295 , A61K39/116
Abstract: The present invention is directed to a adjuvant peptide and uses to facilitate antigen absorption in the mucosa, particularly nasal tissue. Vaccine compositions for mucosal delivery include the adjuvant peptide and an antigen for inducing an immune response.
-
公开(公告)号：WO2005010022A2
公开(公告)日：2005-02-03
申请号：PCT/US2004/022753
申请日：2004-07-15
Applicant: UNIVERSITY OF MARYLAND, BALTIMORE , FASANO, Alessio , VOGEL, Stefanie, N.
Inventor： FASANO, Alessio , VOGEL, Stefanie, N.
IPC: C07K
CPC classification number: C07K14/28 , A61K38/00 , C07K7/06 , G01N33/564 , Y02A50/471 , Y02A50/473 , Y02A50/481 , Y02A50/483 , Y02A50/52
Abstract: Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.
Abstract translation: 已经鉴定了受体蛋白质的激动剂多肽。 激动剂可用于促进药物和抗原吸收。 合适的给药途径包括口服，鼻腔，经皮和静脉内。 药物制剂可以包含与激动剂多肽组合的治疗剂或免疫原性试剂。
-
公开(公告)号：WO2010144140A8
公开(公告)日：2012-01-26
申请号：PCT/US2010001670
申请日：2010-06-10
Applicant: UNIV MARYLAND , FASANO ALESSIO , LAMMERS KAREN , SHEA-DONOHUE TEREZ , GOLDBLUM SIMEON
Inventor： FASANO ALESSIO , LAMMERS KAREN , SHEA-DONOHUE TEREZ , GOLDBLUM SIMEON
IPC: A61K39/395 , A61K31/7105 , A61P1/04 , A61P3/10 , A61P37/00
CPC classification number: A61K31/7105
Abstract: The present invention provides a method of treating an autoimmune disease, comprising the steps of increasing transepithelial electrical resistance leading to decreased cell permeability. Further provided is ajnethod of treating celiac disease in an individual in need of such treatment, comprising the steps of: administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting PAR2.
Abstract translation: 本发明提供一种治疗自身免疫疾病的方法，包括增加跨上皮电阻，导致细胞渗透性降低的步骤。 还提供了在需要这种治疗的个体中治疗乳糜泻的方法，包括以下步骤：施用针对单链佐酮的抗体，从而抑制表皮生长因子受体并抑制PAR2。
-
Patent Agency Ranking6.发明申请USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LONG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME 审中-公开轻度栓塞拮抗剂在治疗急性肺损伤和急性呼吸道综合症中的应用
公开(公告)号：WO2009006246A1
公开(公告)日：2009-01-08
申请号：PCT/US2008068465
申请日：2008-06-27
Applicant: ALEA THERAPEUTICS CORP , PATERSON BLAKE , WARD PETER , FASANO ALESSIO
Inventor： PATERSON BLAKE , WARD PETER , FASANO ALESSIO
Abstract: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.
Abstract translation: 本申请提供治疗急性肺损伤和急性呼吸窘迫综合征的组合物和方法。 所述方法包括向有需要的受试者的肺部施用一个或多个紧密连接的拮抗剂。
-
公开(公告)号：WO2007095091A3
公开(公告)日：2008-09-12
申请号：PCT/US2007003485
申请日：2007-02-09
Applicant: ALBA THERAPEUTICS CORP , EDDINGTON NATALIE D , FASANO ALESSIO , SONG KEON-HYOUNG
Inventor： EDDINGTON NATALIE D , FASANO ALESSIO , SONG KEON-HYOUNG
IPC: A01N37/18
Abstract: The present invention provides compositions and methods for the administration of the compositions to mammals. The compositions comprise therapeutic agents and an intestinal absorption enhancing amount of one or more tight junction agonists. Tight junction agonists include zonulin and/or ZOT receptor agonists. Methods of the invention include orally administering compositions of the invention.
Abstract translation: 本发明提供了将组合物给予哺乳动物的组合物和方法。 组合物包含治疗剂和肠吸收增强量的一种或多种紧密结合激动剂。 紧密结合激动剂包括zonulin和/或ZOT受体激动剂。 本发明的方法包括口服本发明的组合物。
-
8.发明申请USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS 审中-公开使用轻度结节性激素来促进治疗药物的脉搏递送
公开(公告)号：WO2007124354A2
公开(公告)日：2007-11-01
申请号：PCT/US2007066957
申请日：2007-04-19
Applicant: ALBA THERAPEUTICS CORP , FASANO ALESSIO , PATERSON BLAKE
Inventor： FASANO ALESSIO , PATERSON BLAKE
IPC: A61K38/08
CPC classification number: A61K38/08
Abstract: The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pulmonary mucosa.
Abstract translation: 本发明提供了促进治疗剂肺部递送的材料和方法。 在一些实施方案中，紧密连接的激动剂（例如泽宁激动剂）用于组合物以促进治疗剂从肺粘膜摄取。
-
9.发明申请METHOD OF USE OF ANTAGONISTS OF ZONULIN TO PREVENT THE LOSS OF OR TO REGENERATE PANCREATIC CELLS 审中-公开使用ZONULIN拮抗剂以预防损伤或恢复胰腺细胞的方法
公开(公告)号：WO2006135811A3
公开(公告)日：2007-03-08
申请号：PCT/US2006022629
申请日：2006-06-09
Applicant: UNIV MARYLAND , ALBA THERAPEUTICS CORP , FASANO ALESSIO , PATERSON BLAKE , SAPONE ANNA
Inventor： FASANO ALESSIO , PATERSON BLAKE , SAPONE ANNA
IPC: A61K38/00
CPC classification number: A61K35/39 , A61K38/08 , A61K38/18 , A61K2300/00
Abstract: The present invention provides materials and methods for the treatment of diabetes. Using the materials and methods of the invention, the loss of pancreatic ß-cells can be slowed and/or prevented. In addition!, the materials and methods of the invention can be used to regenerate pancreatic ß-cells.
Abstract translation: 本发明提供了治疗糖尿病的材料和方法。 使用本发明的材料和方法，可以减缓和/或阻止胰腺β细胞的丧失。 此外，本发明的材料和方法可用于再生胰腺β细胞。
-
公开(公告)号：WO2006124526A2
公开(公告)日：2006-11-23
申请号：PCT/US2006018281
申请日：2006-05-11
Applicant: UNIV MARYLAND , FASANO ALESSIO
Inventor： FASANO ALESSIO
IPC: G01N33/567 , G01N33/53
CPC classification number: G01N33/566 , G01N33/564 , G01N2800/062
Abstract: The present invention provides materials and methods to assess the efficacy of a treatment. In some embodiments, the present invention provides a method of assessing the efficacy of a treatment for celiac disease by measuring the serum zonulin level of a subject having received the treatment.
Abstract translation: 本发明提供评估治疗功效的材料和方法。 在一些实施方案中，本发明提供了通过测量接受治疗的受试者的血清zonulin水平来评估治疗乳糜泻的功效的方法。
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.017 seconds)
